Boston biotech CEO:
HIPAA + FDA + ISO 13485 + life-sciences compliance vendor forced ranking.
As the CEO of a biotech company in Boston (Kendall Square · Seaport · MIT/Harvard biotech corridor) comparing compliance vendor stacks across HIPAA · FDA QSR · ISO 13485 · IEC 62304 · 21 CFR Part 11 · clinical-data MA HIPAA-equivalent — forced ranking for life-sciences operators · MIT/Harvard spin-out context · operator-honest math.
Longtail cluster · queries this page serves
The forced ranking
#1 Greenlight Guru ($35K-$120K) · MEDTECH-NATIVE GRC · DOMINANT in Boston biotech device side · FDA QSR + ISO 13485 + IEC 62304 + 510(k) workflow · ~45% Boston biotech device adoption
#2 Vanta (HIPAA tier) ($30K-$110K) · Best for software-layer · enterprise hospital customer BAA chain · MIT/Harvard spinout default for cloud SaaS layer
#3 MasterControl ($60K-$200K+) · Larger biotech · validated systems · 21 CFR Part 11 native · #1 for 500+ employee Boston biotech
#4 Veeva Vault Quality ($50K-$180K+) · Pharma-adjacent biotech · validated systems · Boston pharma-spinout fit
#5 Drata (HIPAA tier) ($25K-$95K) · Software-side cloud · engineering-led · cheaper Vanta · MIT engineering-founder cluster fit
#6 Hyperproof ($50K-$180K) · Multi-framework biotech with HIPAA + ISO 27001 + ISO 13485 + NIST layered · HITRUST also if payer scope
#7 Qualio ($30K-$80K) · Modern QMS alternative to MasterControl · smaller Boston biotech fit · 21 CFR 820 + ISO 13485
#8 Scytale (HIPAA + AI) ($22K-$80K) · AI-forward biotech · AI-drug-discovery + ambient-clinical Boston startups
#9 Sprinto (HIPAA) ($15K-$40K) · Pre-Series-A Boston biotech with software-only scope · NOT for device-side
#10 TryComp AI ($10K-$35K) · UNCERTAIN · biotech device-side excludes UNCERTAIN-confidence vendors
Operator-honest claim: Boston biotech standard stack: Greenlight Guru ($35K-$120K · device-side) + Vanta HIPAA ($30K-$110K · software-side) = $65K-$230K/yr software baseline. MIT/Harvard spinouts at Series-A typically run this combo. Class III biotech adds MasterControl. AI-drug-discovery adds Scytale. Pharma-spinout adds Veeva Vault. FDA consultant fees ($75K-$300K) SEPARATE from software · plan accordingly.
MIT/Harvard biotech spinout context
Boston biotech founder pipeline: Heavily driven by MIT + Harvard tech-transfer offices · Whitehead Institute · Broad Institute · Dana-Farber · MGH Research · Brigham + Women's spinouts. TTO license agreements often include ongoing compliance reporting + audit-rights clauses (similar to UCSD spinout context per [[la-jolla-academic-spinout-pso]]).
NIH-funded research scope: Boston biotech often has NIH grant funding · triggers NIST 800-171 implementation for CUI · adds compliance layer beyond commercial baseline. Hyperproof + RegScale lead on NIST 800-171 native mapping.
Pharma-adjacent biotech (Pfizer · Biogen · Moderna alumni): Founders coming out of pharma bring enterprise-grade compliance expectations · default to MasterControl + Veeva Vault patterns even at Series-A scale · overinvestment risk early.
Clinical-site PHI handling: Boston biotech receiving PHI from MGH · Brigham · Beth Israel · Dana-Farber requires BAA execution with each clinical site · BAA chain extends to cloud platform (AWS HIPAA · Azure HIPAA) + analytics tools + observability tools.
Related operator guide:
⚖️ 6 New California AI Laws · Operator Guide